UBS AM’s Alder Biopharmaceuticals ALDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-79,429
| Closed | -$1.5M | – | 2954 |
|
|
2019
Q3 | $1.5M | Sell |
79,429
-677,488
| -90% | -$7.75M | ﹤0.01% | 1748 |
|
|
2019
Q2 | $8.91M | Buy |
756,917
+19,712
| +3% | +$239K | 0.01% | 996 |
|
|
2019
Q1 | $10.1M | Sell |
737,205
-3,562
| -0.5% | -$46.1K | 0.01% | 930 |
|
|
2018
Q4 | $7.59M | Sell |
740,767
-93,289
| -11% | -$1.19M | 0.01% | 947 |
|
|
2018
Q3 | $13.9M | Sell |
834,056
-81,727
| -9% | -$1.48M | 0.01% | 853 |
|
|
2018
Q2 | $14.5M | Sell |
915,783
-46,647
| -5% | -$709K | 0.01% | 854 |
|
|
2018
Q1 | $12.2M | Buy |
962,430
+942,419
| +4,710% | +$13.6M | 0.01% | 880 |
|
|
2017
Q4 | $229K | Hold |
20,011
| – | – | ﹤0.01% | 2241 |
|
|
2017
Q3 | $245K | Buy |
20,011
+8,900
| +80% | +$92.8K | ﹤0.01% | 2165 |
|
|
2017
Q2 | $127K | Hold |
11,111
| – | – | ﹤0.01% | 2319 |
|
|
2017
Q1 | $231K | Hold |
11,111
| – | – | ﹤0.01% | 2121 |
|
|
2016
Q4 | $231K | Sell |
11,111
-9,142
| -45% | -$238K | ﹤0.01% | 2054 |
|
|
2016
Q3 | $664K | Buy |
20,253
+4,400
| +28% | +$134K | ﹤0.01% | 1843 |
|
|
2016
Q2 | $396K | Buy |
+15,853
| New | +$429K | ﹤0.01% | 2083 |
|
|
2016
Q1 | – | Sell |
-8,700
| Closed | -$287K | – | 2685 |
|
|
2015
Q4 | $287K | Hold |
8,700
| – | – | ﹤0.01% | 2361 |
|
|
2015
Q3 | $285K | Buy |
8,700
+300
| +4% | +$12.8K | ﹤0.01% | 2312 |
|
|
2015
Q2 | $445K | Buy |
+8,400
| New | +$306K | ﹤0.01% | 2126 |
|
UBS AM's ALDR Position: Q4 2019 in Review
UBS AM sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 79,429 shares — an estimated $1.5M sold.
UBS AM first reported a position in ALDR in Q2 2015 and held it in 17 quarters. The position peaked at $14.5M in Q2 2018. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.
- UBS AM reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
- UBS AM sold 79,429 Alder Biopharmaceuticals shares in Q4 2019, an estimated $1.5M.
- UBS AM first reported a position in Alder Biopharmaceuticals in Q2 2015 and held it in 17 quarters.
- UBS AM's Alder Biopharmaceuticals position peaked at $14.5M in Q2 2018.
- 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.
Based on UBS AM's 13F filing for Q4 2019, filed 14 Feb 2020.